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Structure based drug design (SBDD)a b s t r a c t
Chagas disease, also called American trypanosomiasis, is a parasitic disease caused by Trypanosoma cruzi
(T. cruzi). Recent findings have underscored the abundance of the causative organism, (T. cruzi), especially
in the southern tier states of the US and the risk burden for the rural farming communities there. Due to a
lack of safe and effective drugs, there is an urgent need for novel therapeutic options for treating Chagas
disease. We report here our first scientific effort to pursue a novel drug design for treating Chagas disease
via the targeting of T. cruzi tubulin. First, the anti T. cruzi tubulin activities of five naphthoquinone deriva-
tives were determined and correlated to their anti-trypanosomal activities. The correlation between the
ligand activities against the T. cruzi organism and their tubulin inhibitory activities was very strong with a
Pearson’s r value of 0.88 (P value <0.05), indicating that this class of compounds could inhibit the activity
of the trypanosome organism via T. cruzi tubulin polymerization inhibition. Subsequent molecular mod-
eling studies were carried out to understand the mechanisms of the anti-tubulin activities, wherein, the
homology model of T. cruzi tubulin dimer was generated and the putative binding site of naphthoquinone
derivatives was predicted. The correlation coefficient for ligand anti-tubulin activities and their binding
energies at the putative pocket was found to be r = 0.79, a high correlation efficiency that was not repli-
cated in contiguous candidate pockets. The homology model of T. cruzi tubulin and the identification of its
putative binding site lay a solid ground for further structure based drug design, including molecular dock-
ing and pharmacophore analysis. This study presents a new opportunity for designing potent and selec-
tive drugs for Chagas disease.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chagas disease, also called American trypanosomiasis, which
can affect both animals and humans, is caused by the protozoan
parasite Trypanosoma cruzi. The disease is endemic in South Amer-
ica; however, due to population mobility, it is also significant in the
US.1 Recent reports indicate that of the Chagas disease cases tested
on blood donors in Texas, 36% were acquired locally. Furthermore,73% of tested triatomine insects from 11 counties in Texas were
found to be positive for T. cruzi.2 A separate study reported a T. cruzi
infection rate of 8.8% in sheltered dogs in Texas.3 Other studies
have corroborated this abundance of T. cruzi in vectors and animal
carriers in Texas,4 and the high correlation between human and
dog infection (r2 = 0.955).5 These findings point to a high reservoir
of T. cruzi in the Southern tier states of the US,6 and a likely under-
estimation of the prevalence of this disease in the US, including
this region in particular.
Chagas disease is ranked as the third most widely spread trop-
ical disease following malaria and schistosomiasis.7 However,
3850 C. O. Ogindo et al. / Bioorg. Med. Chem. 24 (2016) 3849–3855unlike malaria and schistosomiasis, both of which have safe and
effective treatments, the drugs for Chagas disease, benznidazole
and Nifurtimox, are neither FDA approved nor safe or effective.8
Chagas disease has two distinct clinical phases, an acute and a
chronic phase. The acute phase occurs in the first two months of
infection8 and is diagnosed by a positive parasitological and molec-
ular based test for the parasite T. cruzi. Once detected it can be
cured by use of both of the drugs. After the acute infection, the dis-
ease enters into an asymptomatic chronic phase. The chronic phase
is diagnosed by serological based immunoassay techniques and
characterized by undetectable levels of the parasite. Of the chronic
cases, 30% will develop the pathological conditions of the disease.
The efficacy of the two drugs’ markedly diminish with the length of
the chronic infection, more so in adults than in children seventeen
years and younger.9 In addition, these treatments cause adverse
side effects in 40% of the infected which necessitate the physicians’
cessation of treatment.8 Combined with the fact that the diagnosis
of Chagas disease usually occurs years or even decades post onset
of infection, it is crucial that safe and effective drugs be developed
that can enable treatment at both the acute and chronic stages of
the disease.
Naphthoquinone natural products comprise diverse structures
known to possess a number of useful biological activities including:
anti-viral, anti-fungal,10 anti-neoplastic,11 anti-hypoxic,12 anti-
ischemic,13 anti-platelet, anti-inflammatory, and anti-allergenic
activities13 and have been investigated for their anti-trypanosomal
activities.14 A recent study showed that imido-substituted
1,4-naphthoquinones are more potent anti-trypanosomal agents
than the clinically used Nifurtimox by the arrest of T. cruzi cell
proliferation at the G2/M phase.15 Since the cell cycle arrest pointed
to a tubulin disruptive process, we hypothesized that the anti-
trypanosomal activities occurred via T. cruzi tubulin polymerization
inhibition, an idea that provided the impetus to pursue a novel drug
design for Chagas disease via the targeting of T. cruzi tubulin.
Microtubules are ubiquitous cellular polymers made up of two
chains of tubulin dimers (a/b) that exhibit a characteristic dynamic
instability. The dynamic instability is a state of perpetual stochastic
reversions among periods of growth, shortening and pauses that
imbue the microtubules with their cellular functionalities. For
example, the spindle apparatus formed by microtubules is respon-
sible for the separation of replicated chromosomes with high
integrity into two daughter cells during mitosis. Hence, micro-
tubules have been used as a validated target for anticancer
chemotherapy.16 By extension, targeting the parasite tubulin is a
theoretically viable approach to the treatment of parasitic diseases.
Indeed, the anti-protozoal activities of benzimidazoles have been
correlated to b-tubulin sequences.17 The work of Chan et al.18
sought to harness the anti-tubulin properties of certain herbicides
to target trypanosomatid protozoans and the parasite Leishmania
mexicana,19 while George et al.20 followed the same approach for
the treatment of the African trypanosomes. Targeting tubulin is
one of the viable and promising techniques for anti-parasite drug
design.
The research reported here is focused on bioassay and molecu-




The anti T. cruzi tubulin activities of five newly synthesized
ligands were determined by using biological analyses as stated
below. The biologically determined anti T. cruzi tubulin activitieswere then correlated with their respective anti-trypanosomal
activities.
2.1.1. Tubulin purification
The method of MacRae and Gull21 was used for the purification
of tubulin from T. cruzi. Briefly, PBS washed parasites were resus-
pended in 7 ml of PEME buffer (100 mM PIPES, pH 6.9, 2 mM EGTA,
1 mM MgSO4, and 0.1 mM EDTA) supplemented with 4 M glycerol,
0.1 mM GTP, and 50 lg/ml leupeptin. The resuspended parasites
were sonicated 4  30 s, with 2 min cooling intervals between
bursts (BRANSONIC 50/60 Hz, 80 Watts) and centrifuged twice at
40,000g for 30 min at 4 C (BECKMAN induction drive centrifuge
model J2-21M). The resulting cell-free supernatant fraction was
loaded into DEASE-Sephadex column (Sigma, DFF 100 DEAE-
Sepharose) equilibrated with PEME buffer supplemented with
0.2 M KCl, 0.1 mM GTP, and 12.5 lg/ml leupeptin. The column
was washed with the equilibrium buffer after adding the sample
and tubulin was eluted with PEME buffer with 0.6 M KCl, 0.1 mM
GTP, and 12.5 lg/ml leupeptin. The peak eluted fractions were
pooled and concentrated to 800–900 ll utilizing an Amicon
Ultra-5 centrifugal filter device (MILLIPORE UFC9 030 08). Protein
concentrations were determined using a BCA Protein Assay Kit
(Pierce, 23225) according to the manufacturer’s instructions using
Bovine Serum Albumin (BSA) as a standard.
2.1.2. Polymerization assay
T. cruzi tubulin polymerization assays were performed accord-
ing to the procedures of Yakovich et al.22 Polymerization reactions
were conducted in buffer containing 0.1 M PIPES (pH 6.9), 1 mM
EGTA, 5 mM MgCl2, 1.2 mg/ml purified T. cruzi tubulin, and differ-
ent concentrations of the 3-chloro,2-imido-substituted 1,4-naph-
thoquinones (IMNDQ) (0.6–40 lM in 50% DMSO). Components of
the reaction mixture were added to a 96-well microplate in a final
volume of 50 ll, incubated at room temperature for 15 min, and
then placed at 4 C for 5 min. Polymerization was initiated by add-
ing 1 mM GTP, and assayed photometrically by measuring the
absorbance at 405 nm using a microplate reader at 30 C.
2.1.3. Statistical analysis
All experiments were done in triplicate and the means and stan-
dard errors (SE) were determined. Data were analyzed by one way
ANOVA using excel with the Analysis ToolPak add-in activated.
P < 0.05 was considered significant.
2.2. Molecular modeling
The host terminal computer used was equipped with Microsoft
Windows 7 Professional OS and an Intel Xeon 3.40 GHz dual pro-
cessor with 64.0 GB physical memory. All molecular modeling
studies were performed with Molecular Operating Environment
software (MOE 2013.0802).23 Default parameters were used unless
specified otherwise.
2.2.1. Homology modeling
The protein sequences of T. cruzi were mined from UniProtKB.
The atom coordinates of the template protein 1JFF were down-
loaded from the RCSB Protein Data Bank. The homology modeling
protocol entailed sequence alignment and matching model
sequences with template sequences. The modeling was done with
parameters selected to disable C-terminal and N-terminal outgap
modeling, as well as the inclusion of selected ligand environments
for induced fit and automatic detection of disulfide bonds. Proto-
nate 3D was applied prior to energy minimization of the final
model. Homology model validation was carried out by Phi-Psi plot
of the model.
Table 1
Anti-trypanosomal and anti Trypanosoma cruzi tubulin activities of five imido-1,4-
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The Site Finder algorithm built into MOE was used to calculate
the possible binding sites in the model. Site Finder implements a
geometric method where relative positions and accessibility of
the receptor atoms are taken into account along with their chem-
ical classifications. It is based upon finding alpha shapes, which
generally identify regions of tight atomic packing; filtering alpha
shapes that are exposed; classifying alpha shapes as hydrophobic
or hydrophilic; clustering alpha spheres and rating the sites
according to their probability for ligand binding.24
2.2.3. Putative binding site prediction
The putative active site is defined as the binding pocket in
which the binding energies of tested ligands correlate with the
inhibition activities of the ligand in assay experiments. In order
to identify the putative pocket for the IMDNQ (3-chloro,2-imido-
substituted 1,4-naphthoquinones) ligands, five compounds:
IMDNQ1, IMDNQ2, IMDNQ3, IMDNQ10 and IMDNQ11 were
docked into the three pockets, respectively. The docking procedure
was followed as recommended by MOE analysis using forcefield
Amber:12 EHT. The receptor was prepared by modeling missing
residues and protonated using Protonate3D. Tethered energy min-
imization was also carried out. To perform docking studies, ligands
were converted into an MDB file format and the energy was min-
imized. The differing ligand conformations were generated by rota-
tion of all rotatable bonds. Docking was done using the Triangle
Matcher protocol. The forcefields used to refine poses were London
dG for rescoring and GBVI/WSA dG for rescoring.23 Duplicate poses
were removed and 30 poses with lower energy were retained as
best poses. When required, pharmacophore constraints were
included to guide placement or to filter poses. The best poses were
used in the evaluation of energy stabilization and ligand binding
mode for the further calculation of correlation efficiency.
3. Results and discussion
3.1. Bioassay
As discussed in the introduction, certain naphthoquinones exhi-
bit anti-trypanosomal activities. For example, the naturally occur-
ring naphthoquinone lapachol and some of its derivatives show
trypanocidal activity against T. cruzi.25 Additionally, some naph-
thofuranquinones were found to be active against epimastigote
and trypomastigote forms of T. cruzi.26 Similarly, 2,3-diphenyl-
1,4-naphthoquinone (DPNQ), was found to be effective against T.
cruzi.14 Previously, some novel imido-1,4-naphthoquinone deriva-
tives,15 were synthesized and investigated for anti-trypanosomal
activities. Some of them showed remarkable anti-trypanosomal
activity at G2/M of the cell cycle.15 Since the cell cycle arrest
pointed to tubulin disruptive processes, experiments were
designed to evaluate activities of five selected imido-1,4-naphtho-
quinone ligands against T. cruzi tubulin assembly (Table 1). The
anti T. cruzi tubulin activities of the ligands IMDNQ1, IMDNQ2,
IMDNQ3, IMDNQ10 and IMDNQ11 were determined and corre-
lated with their anti-trypanosomal activities. As shown in Table 1,
the previously determined anti-trypanosomal activities gave IC50s
of 2.77, 4.83, 0.70, 2.23 and 6.10 lM, respectively. Similarly, their
activities against T. cruzi tubulin polymerization gave IC50s of 6,
12, 3.2, 8, and >40 lM, respectively. Compound IMDNQ11 was
the least potent and least selective. IMDNQ11 was included in
the tubulin assembly inhibition experiments for comparative pur-
poses. The most potent IMDNQ, IMDNQ3, has an anti-trypanoso-
mal IC50 of 0.70 lM and was also determined to be the most
active in inhibiting T. cruzi polymerization with an IC50 of
3.2 lM. Similarly, the least potent derivative, IMDNQ11 with ananti-trypanosomal IC50 of 6.10 lM exhibited the least anti-tubulin
activity with an IC50 of >40 lM. IMDNQ1, IMDNQ2 and IMDNQ10
showed anti-tubulin IC50 values of 6, 12, and 8 lM, respectively.
Figure 1 shows that a correlation was established between anti-
trypanosomal activities of the imido-1,4-naphthoquinone deriva-
tives and their activities toward T. cruzi tubulin inhibition, with a
correlation coefficient of r = 0.88, P value = 0.55. The results show
strong evidence that this class of compounds inhibits the try-
panosome organism via T. cruzi tubulin polymerization inhibition.
3.2. Molecular modeling
The study of molecular modeling is indispensable in under-
standing the mechanism of inhibition of T. cruzi tubulin and the
facilitation of designing lead compounds (drugs) for treating Cha-
gas disease. To understand how the 2-imido-1,4-naphthoquinone
derivatives with anti-trypanosomal activities27,28 inhibited T. cruzi
tubulin, the 3D structure of the T. cruzi tubulin dimer was homol-
ogy modeled, and subsequently, the modeled dimer was used in
molecular docking studies to examine the nature of the receptor-
ligand binding mode.
3.2.1. Sequence determination
In order to carry out homology modeling, the sequences of the
target protein chains of T. cruzi tubulin (a chain and b chain)
are required, as well as the 3D structure of the template homolog.
Figure 1. The correlation coefficient of Anti-trypanosomal Log(IC50) and anti
Trypanosoma cruzi tubulin Log(IC50) is r = 0.88.
3852 C. O. Ogindo et al. / Bioorg. Med. Chem. 24 (2016) 3849–3855Protein sequences of T. cruzi were mined from UniProtKB (www.
uniprot.org), and are identified by their accession numbers. Figure 2
shows the sequence alignment of alpha chains and beta chains
from different database entries of T. cruzi tubulin. The amino acid
lengths of the alpha chains, Q27352TBA is labeled as 1a;
Q26973TBA labeled as 2a and Q8T9X5TBA labeled as 3a are 451,
425 and 451, respectively. The lengths of the beta chains, P08562
labeled as 1b; Q4DQP2 labeled as 2b and Q8STF3 labeled as 3b
are all composed of 442 amino acids. Chain alignments gave a pair-
wise residue identity of 99.3% between 1a and 2a; 99.6% between
1a and 3a; and 98.8% between 2a and 3a. Residue variation of the
alpha chains were found at positions 376 (CYS to SER) and 425
(LEU to TRP) for 2a and positions 215 (ARG to ALA) and 270 (SER
to THR) for 3a. Similarly, the beta chains are highly conserved, with
pairwise alignment giving values of residue conservation between
99.1 and 99.8%. The beta chains have residue variations at 274 on
1b, where SER replaces THR, and at 288 and 289, where SER andFigure 2. Sequence alignment oVAL are replaced by GLU and LEU, respectively, and finally, at
306 (ALA to ARG). Additionally, 3b has residue variation at 103
(LYS to GLN). All the variations identified in the a and b chains
were either conserved or remotely located from the putative active
site such that their effect(s) on ligand binding would remain lar-
gely insignificant. Consequently, our model of a 1a1b dimer was
held as a representative dimer for the nine possible dimer
combinations.
3.2.2. Homology modeling
The Bos taurus tubulin structure from the RCSB Protein Data
Bank ID 1JFF is a homolog of T. cruzi tubulin, with 80% residue sim-
ilarity and a well resolved 3D structure.29 In addition it possesses a
straight tubulin dimer structure similar to a functional micro-
tubule unit, therefore, it is a good choice for a 3D template for
modeling the target T. cruzi tubulin dimer. The sequence alignment
of T. cruzi tubulin and Bos taurus tubulin gave a pairwise residue
identity of 83.7% and 84.8% for the a and b chains, respectively.
This high residue similarity attests to the appropriateness of the
template for the generation of a good model because residue sim-
ilarity is a good predictor of structure similarity.30
Homology modeling was carried out using the aforementioned
protocol in methodology. The resulting homology model of the tar-
get protein shows retained ligands in respective binding sites.
The forcefield Amber12:EHT modules implemented in MOE
with parameters enabled for bonded, van der Waals, electrostatic
and restraints terms were loaded and used to prepare the template
structure by modeling the missing residues on the alpha chain resi-
dues at 34–60, 440–450 and beta chain 427–445. This was fol-
lowed by automatic protonation and tethered minimization with
a deviation constraint of 0.5 Å for all atoms. Insertions and dele-
tions were modeled from fragments of high resolution chains from
the Protein Data Bank which superposes well onto anchor residues
on either side of the insertion area.31 Loops were modeled with
their original substrates/ligands, GTP, GDP and taxol, retained to
maintain the model environment. Ten intermediate models weref Trypanosoma cruzi tubulin.
Figure 4. Model validation by Phi–Psi plot showing that the Phi–Psi plot cluster of
the model is of high quality with minimal outliers.
Figure 5. The modeled structure of the Trypanosoma cruzi tubulin dimer showing
candidate binding pockets in between chains. Pocket 1 is highlighted in yellow,
pocket 2 in green, and pocket 3 in red. Pocket 1 is the putative binding pocket for
IMDNQ ligands.
C. O. Ogindo et al. / Bioorg. Med. Chem. 24 (2016) 3849–3855 3853generated and the average backbone coordinates of the models
were determined. The root mean square deviation, RMSD, of each
intermediate model to the average positions for all the intermedi-
ate models was used as criteria for selecting the working model.
Hence, the final homology model was the one with the smallest
RMSD following the defined criteria.
Figure 3 shows the homology model of the T. cruzi tubulin
dimer with the ligands GDP, GTP and taxol in the respective bind-
ing sites which have been retained for induced fit.
Finally, the Phi–Psi dihedral angle plot was used to validate our
final model. The Phi–Psi dihedral angle plot provides an indepen-
dent method to evaluate the conformational quality of the protein
structure and offers a visual representation of any dihedral angle
outliers in the model structure.23 The plots use a MOE reference
database of a selected 129,858 residues derived from 556 protein
structures. A Z-Score threshold of 4 (99.99%) was applied in which
the favored regions are rendered green and the allowed but disfa-
vored regions are rendered yellow while the outliers are rendered
red. Figure 4 is the result of the evaluation of the dihedral angles of
the homology model and shows that the Phi–Psi plot cluster of the
homology model is of high quality with minimal outliers.
3.2.3. Pocket discovery
The homology model of this study serves as a means to uncover
candidate pockets for the binding of IMDNQ ligands to the target
protein. Pocket discovery, carried out by the Site Finder algorithm
in the MOE module, revealed three pockets between the tubulin a
and b chains, as shown in Figure 5. Pocket 1 is located on one side
of the inter-dimer region, while pockets 2 and 3 are located at the
other end diametrically opposite to the first pocket. Pockets 2 and
3 are partially overlapping and, therefore, upon docking produced
similar energy profiles. All the candidate pockets lie between the
chains and interact with residues of both chains.
In order to identify the putative pocket for the IMDNQ ligands,
the three pockets were docked with the ligands IMDNQ1, IMDNQ2,
IMDNQ3, IMDNQ10 and IMDNQ11. Again these ligands have
known T. cruzi tubulin inhibition IC50s of 8, 12, 3.2, and >40 lM,
respectively. The binding energy profiles for the ligands in the
three pockets are shown in Figure 6A. Correlations were calculated
between the binding energies of the ligands in each of the pockets
and the natural log of IC50, with pocket 1 showing a good correla-
tion as shown in Figure 6B. The putative active site is defined as the
binding pocket which gives energy stabilizations that correlate
with inhibition activities in assay experiments (Table 2). The calcu-
lations showed that the correlation coefficient between receptor-
ligand stabilization energy and tubulin polymerization inhibition
(logIC50) of pocket 1 is 0.79 while the other two contiguous bind-
ing pockets showed no correlation between binding energy and
activity. Hence, pocket 1 was designated as the putative binding
pocket for IMDNQ ligands bound in the T. cruzi tubulin. The highFigure 3. Homology model of Trypanosoma cruzi tubulin dimer with substrates/
ligands GDP (highlighted in green), GTP (highlighted in yellow) and taxol
(highlighted in red) retained in their original respective binding sites.correlation coefficient of 0.79 at the putative binding pocket is
remarkable and provides strong evidence that the site is involved
in the inhibition of T. cruzi tubulin polymerization and, hence,
the corollary inhibition of the T. cruzi organism.
As shown in the close up view of the predicted putative binding
site (Fig. 7), the loop of the sequences from a96 to a103 (high-
lighted in the purple ribbon) is located inside the pocket 1, right
next to the bound GTP molecule. Therefore it has been shown that
within this loop, residue 101 interacts with the GTP pocket on the
N site of the a-chain while residues 97, 98, 100 and 102 interact
with the IMDNQ molecules. This means that the putative binding
site of the IMDNQ ligands (in the yellow shadow) share the loop
on the alpha chain with the N site for GTP.
Additionally, the loop of residues 251–263 on the b chain (high-
lighted as the green ribbon) in the IMDNQ binding site overlaps
with the colchicine binding site (buried deep at the midsection of
the inter-dimer region), shifted into the b chain side on the loop
248–255. This is very important and interesting information for
the design of highly potent but low toxic drugs for the potential
Figure 6. (A) Energy profiles for ligands 1–5, representing IMDNQ1, IMDNQ2, IMDNQ3, IMDNQ10, and IMDNQ11 in Pockets 1, Pocket 2 and Pocket 3. (B) Binding energy
associated with anti-Trypanosoma cruzi tubulin Ln(IC50) for the putative pocket (pocket 1).
Table 2










Figure 8. The interactions between the ligand IMNDQ3 and the putative binding
pocket. The hydrogen bonds formed between amide groups of the ligand with the
guanylyl hydrogens of Arg156 and the hydrogen of the imidazole group of His406
are highlighted as green lines. The pi–pi interactions between the pi rings of
naphthoquinone moiety on the ligand and the pi ring of the indole group of Tryp407
is highlighted as a blue line.
3854 C. O. Ogindo et al. / Bioorg. Med. Chem. 24 (2016) 3849–3855treatment of Chagas disease. As previously discussed, tubulin
dynamics is a promising target for new chemotherapeutic agents
and the colchicine binding site is one of the most important pock-
ets for potential human tubulin polymerization destabilizers.32 In a
comparison of the T. cruzi tubulin model produced in this study
with the Bos taurus tubulin protein structure (complexed with col-
chicine) obtained from RCSB PDB ID 1SAO,33 it is revealed that
pocket 2 of this study’s model coincides with the B. taurus colchi-
cine binding site. Hence, the predicted putative binding site of
naphthoquinone based ligands is different from the colchicine
binding site which is implicated in the inhibition of human tubulin
polymerization. An effective drug would typically attack the para-
site and remain harmless to the host, therefore, an ideal approach
to drug design would be to identify target proteins that are either
present only in the parasite, or alternatively, have three dimen-
sional structures which are sufficiently different from the corre-
sponding host proteins. Therefore, the revelation of the
differences between the putative binding site for the naphtho-Figure 7. The close up view of pocket 1, the predicted putative binding site. The
loop of residues from 96 to 103 on the a chain is shown in the purple ribbon and the
loop of residues from 251 to 263 on the b chain is shown in the green ribbon. The
GTP molecule at the N site is also included as a light pink stick model.quinone based ligands and the colchicine binding site of the human
tubulin polymerization inhibitors is a very important finding that
presents a novel opportunity for ligand selectivity enhancement
and reduction of toxicities of future drugs for Chagas disease.
The major interactions exhibited by IMDNQ1, IMDNQ2,
IMDNQ3, IMDNQ10 and IMDNQ11 binding in the putative pocket
consisted mainly of the donor–acceptor interactions of Arg156 on
the b-chain and His406 on the a-chain with the imido side groups
of the ligands, and the hydrophobic pi–pi interactions of the fused
pi rings of the naphthoquinone moiety and the pi ring of the
Trp407 residue on the a-chain. For example, Figure 8 shows the
major interactions found in the binding mode of IMDNQ3 are
two hydrogen bonds between one amide group of the ligand and
the Arg156 hydrogen; one hydrogen bond between another amide
group and the His406 hydrogen; and a pi–pi interaction between
the naphthoquinone pi ring and the pi ring of Trp407. The opti-
mization of the aforementioned major interactions and the general
fit of the ligands in the binding pocket seem to explain the
observed greater stabilization of the most active ligand IMDNQ3.
Further investigation of these interactions will be carried out and
reported in a subsequent publication.
4. Conclusions
The activities of five previously synthesized 3-chloro,2-imido-
1,4-naphthoquinone ligands, namely, IMDNQ1, IMDNQ2, IMDNQ3,
C. O. Ogindo et al. / Bioorg. Med. Chem. 24 (2016) 3849–3855 3855IMDNQ10 and IMDNQ11, against T. cruzi tubulin assembly were
examined and determined. It was found that IMDNQ3 possessed
the most potent anti-trypanosomal activity with an IC50 of
0.70 lM. IMDNQ3 was also determined to be the most active com-
pound in inhibiting T. cruzi polymerization with an IC50 of 3.2 lM.
Similarly, the least potent derivative, IMDNQ11, has an anti-try-
panosomal IC50 of 6.10 lM and it exhibited the least anti-tubulin
activity with an IC50 of >40 lM. A correlation of r = 0.88 (P value
<0.05) was established between anti-trypanosomal activities of
the imido-1,4-naphthoquinone derivatives and their activity
toward T. cruzi tubulin inhibition. These findings provide strong
evidence that this class of compounds inhibit the trypanosome
organism via T. cruzi tubulin polymerization inhibition.
In order to understand the mechanism of tubulin inhibition and
use it for drug design, a homology model of the T. cruzi tubulin
dimer was created and the putative binding site of this class of
naphthoquinone derivatives was predicted. The correlation coeffi-
cient for ligand anti-tubulin activities and their binding energies at
the putative pocket were evaluated and found to be strong
(r = 0.79), a high correlation efficiency not replicated in other con-
tiguous candidate pockets. Moreover, the relative locations of the
IMDNQ binding site in T. cruzi tubulin and the colchicine binding
site in human tubulin were described and compared, thereby pro-
viding important information useful in the design of drug
selectivity.
In conclusion, the identification of the binding pocket is impor-
tant because it enables elucidation of pharmacophore features
which allows for the characterization of receptor–ligand com-
plexes in the putative binding pocket. Additionally, the formula-
tion of a pharmacophore query can be employed to design
potent drug candidates or to search databases of ligands in order
to identify candidate molecules for treatment of Chagas disease.
The creation of a homology model of T. cruzi tubulin and the dis-
covery of the putative binding site of the naphthoquinone based
ligands provides a basis for pharmacophore feature analysis and
selectivity enhancement of the drug candidates. This study opens
a novel approach to the design of high potent, but low toxic drugs
for the treatment of Chagas disease.
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